Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~* Relapsed disease after definitive local therapy, as documented only by a rise in prostate-specific antigen (PSA)~  * Experienced PSA relapse after definitive local therapy~ * Rising PSA (≥ 1.0 ng/mL after nadir \< 1.0 ng/mL)~    * PSA increase of ≥ 0.3 ng/mL (increase occurred between 2 separate measurements taken ≥ 4 weeks apart)~ * The first of these two PSA values must rise above a previously recorded post-therapy nadir value~* Ineligible for curative therapy~* No clinical evidence of local recurrence (i.e., palpable induration or mass in the prostatic fossa) other than PSA elevation~* No evidence of palpable disease in the prostatic bed~* No metastatic disease (M0)~  * No non-nodal (\> N1) metastasis~ * No evidence of osseous metastasis on bone scan within the past 28 days~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* ECOG 0-1~Life expectancy~* At least 1 year~Hematopoietic~* Platelet count ≥ 30,000/mm\^3~* Absolute neutrophil count ≥ 1,000/mm\^3~Hepatic~* No known hepatitis B or C positivity~Renal~* Creatinine clearance ≥ 30 mL/min~Immunologic~* No known human T-cell lymphotropic virus positivity~* No hypersensitivity to bortezomib, boron, or mannitol~* No known HIV 1 or 2 positivity~* No active, ongoing bacterial, viral, or fungal infection~Other~* Fertile patients must use effective contraception~* No peripheral neuropathy ≥ grade 2~* No other disease, condition, or social or geographic constraint that would preclude study participation~* No other malignancy within the past 5 years except basal cell or squamous cell skin cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No concurrent chemotherapy~Endocrine therapy~* See Disease Characteristics~* At least 6 months since prior hormonal therapy combined with radiation therapy as definitive therapy~* Neoadjuvant hormonal therapy prior to definitive therapy (e.g., surgery, radiation therapy, brachytherapy, or cryoablation) allowed~* No other concurrent hormonal therapy~Radiotherapy~* See Disease Characteristics~* More than 12 months since prior radioactive seed therapy~* No concurrent radiotherapy~Surgery~* See Disease Characteristics~* More than 4 weeks since prior surgery~* No concurrent surgery~Other~* No concurrent second-line herbal preparations, including PC-SPES~* No other concurrent investigational agents

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Velcade (Type: EXPERIMENTAL): Patient will complete Part A (Velcade only). If the patient has a complete response, he will come off study. If the patient has progressive disease, he will start Part B (Velcade + antiandrogen). If the patient has a partial response or stable disease, he will start Part B after at least a 7-day break.
- Part B: Velcade+LH-RH antagonist+Androgen receptor antagonist (Type: EXPERIMENTAL): Patient will start Part B after completing Part A or may be enrolled to part B only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues